In a groundbreaking study from Osaka University, researchers report that tricaparin, a common dietary supplement, has led to remarkable clinical improvements in two patients with triglyceride deposit cardiomyovasculopathy (TGCV), a rare form of coronary artery disease characterized by intracellular triglyceride build up. Both patients experienced significant relief from refractory angina and marked regression of diffuse coronary atherosclerosis on imaging without changes in blood cholesterol levels. These findings suggest a novel treatment approach via intracellular lipolysis rather than conventional serum lipid modulation, highlighting tricaprin’s potential for TGCV and offering hope for patients who do not respond to existing therapies. 8
References
1. Quaade AS, et al. Contact Dermatitis. 2021;84:361–374. 2. Grant L, et al. Adv Ther. 2020;37(2):692-706. 3. Dalgard FJ, et al. J Invest Dermatol. 2015;135(4):984-991. 4. Cortesi PA, et al. Contact Dermatitis. 2014;70(3):158-168.5. Bissonnette R, et al. Lancet. 2024;404:461-473. 6. NCT06004050. ClinicalTrials.gov. Accessible from: https://clinicaltrials.gov/study/NCT06004050. 7. Kato K, et al. NPJ Aging. 2025;11(1):55. 8. Hirano KI, Higashi M, Nakajima K. Eur Heart J. 2023 Apr 1;44(13):1191. 9. Qi J, et al. Nat Med. Published online July 2, 2025. doi:10.1038/s41591-025-03773-w. 10. Pryor JL, et al. J Strength Cond Res. 2024;38(7):1350-1357.
